Lyme Disease Treatment Pipeline Analysis 2025

DelveInsight's "Lyme Disease Pipeline Analysis 2025" delivers extensive intelligence on over 7 pharmaceutical firms and more than 7 investigational medications within the Lyme Disease development arena. The analysis encompasses profiles of Lyme Disease Pipeline therapeutic candidates, spanning both clinical and preclinical phases. Additionally, it includes evaluation of Lyme Disease Pipeline Therapeutics by product category, developmental phase, administration method, and molecular classification. The report also spotlights dormant development programs in this therapeutic area.

Interested in recent developments within the Lyme Disease Pipeline? Discover the emerging treatments and clinical studies generating attention @ Lyme Disease Pipeline Outlook Report

Primary Highlights from the Lyme Disease Pipeline Analysis

• On September 29, 2025, Pfizer initiated a clinical investigation to evaluate a 6-valent OspA-based Lyme disease vaccine (VLA15) for prevention of Lyme disease within North America and Europe. Approximately 9,400 healthy participants (this number excludes participants from 8 sites which were terminated for quality issues) 5 years and older will be recruited from areas with high levels of endemic Lyme disease to receive VLA15 or placebo (an inactive substance consisting of saltwater). Each participant will have approximately a 50% chance of receiving VLA15 and approximately a 50% chance of receiving placebo.

• DelveInsight's Lyme Disease Pipeline analysis reveals a dynamic field featuring more than 7 engaged entities advancing over 7 investigational treatments for Lyme Disease management.

• Major Lyme Disease pharmaceutical firms include Valneva, Cortene, Blue Lake Biotechnology, Tarsus Pharmaceuticals, Inovio Pharmaceuticals, Aegis Life, Abzyme Therapeutics, among additional organizations.

• Notable Lyme Disease investigational medications include TP-05, Amoxicillin, SHB001, VLA15, mRNA-1975, VLA15, among others.

Curious about which pharmaceutical companies are pioneering advancement in Lyme Disease treatment? Explore comprehensive pipeline intelligence @ Lyme Disease Clinical Trials Assessment

The Lyme Disease Pipeline Analysis delivers a condition synopsis, pipeline landscape, and therapeutic evaluation of principal investigational therapies within this domain. The analysis also emphasizes unaddressed medical requirements concerning Lyme Disease.

Lyme Disease Background

Lyme disease is the most prevalent vector-borne disease in the United States. Lyme disease is caused by the bacterium Borrelia burgdorferi and rarely, Borrelia mayonii. It is transmitted to humans through the bite of infected blacklegged ticks. Typical manifestations include fever, headache, fatigue, and a characteristic skin rash called erythema migrans. If left untreated, infection can extend to joints, the heart, and the nervous system. Lyme disease is diagnosed based on symptoms, physical findings (e.g., rash), and the possibility of exposure to infected ticks. Laboratory testing is beneficial if used correctly and performed with validated methods. Most cases of Lyme disease can be managed successfully with a few weeks of antibiotics. Steps to prevent Lyme disease include using insect repellent, removing ticks promptly, applying pesticides, and reducing tick habitat. The ticks that transmit Lyme disease can occasionally transmit other tickborne diseases as well.

Lyme Disease Investigational Drug Profiles

VLA 15: Valneva

VLA15 is presently the only active vaccine program in clinical development against Lyme disease. VLA15 is a multivalent recombinant protein vaccine that targets six serotypes of Borrelia representing the most common pathogenic strains found in the United States and Europe. Valneva has completed recruitment and reported initial results for two Phase 2 clinical trials of VLA15 in over 800 healthy adults and in which Valneva observed high levels of antibodies against all six serotypes. Valneva announced a collaboration with Pfizer for late phase development and, if approved, commercialization of VLA15. As part of its collaboration with Pfizer, Valneva accelerated the pediatric development of VLA15 with an additional Phase 2 clinical trial initiated in March 2021. In July 2021, Pfizer and Valneva announced recruitment completion for VLA15-221 with a total of 625 participants, 5 to 65 years of age. The VLA15 program was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) in July 2017.

CT38: Cortene

CT38 is a potent, short-lived, peptide agonist selective for CRFR2. It is composed entirely of naturally-occurring amino acids. It was tested in animals and in healthy humans in a Phase 1 clinical trial. These investigations have defined the safety profile of CT38 in humans and demonstrate that CT38 only lasts a few hours in the body.

Monitoring active Lyme Disease Clinical investigations? This announcement is essential reading. Access the latest advances @ Lyme Disease Treatment Drugs

The Lyme Disease Pipeline Analysis Offers Intelligence On:

• The analysis delivers detailed intelligence regarding pharmaceutical companies developing therapeutics for Lyme Disease management, including cumulative therapies created by each organization for this indication.

• It evaluates various therapeutic candidates categorized into early-phase, mid-phase, and late-phase development for Lyme Disease Treatment.

• Lyme Disease pharmaceutical firms engaged in targeted therapeutic development with corresponding active and inactive (dormant or terminated) initiatives.

• Lyme Disease investigational medications classified by developmental phase, administration method, target receptor, monotherapy or combination therapy, distinct mechanism of action, and molecular classification.

• Comprehensive analysis of partnerships (company-to-company collaborations and company-to-academia partnerships), licensing arrangements, and funding particulars for future progression of the Lyme Disease market.

Lyme Disease Pharmaceutical Firms

Valneva, Cortene, Blue Lake Biotechnology, Tarsus Pharmaceuticals, Inovio Pharmaceuticals, Aegis Life, Abzyme Therapeutics, among additional organizations.

The Lyme Disease Pipeline analysis presents therapeutic evaluation of investigational medications by Administration Method. Products are classified under multiple administration routes including:

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Lyme Disease products are classified under various molecular categories including:

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

From investigational drug candidates to competitive intelligence, the Lyme Disease Pipeline Analysis encompasses comprehensive insights - review it today @ Lyme Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Lyme Disease Pipeline Analysis

• Coverage: Global

• Lyme Disease Pharmaceutical Firms: Valneva, Cortene, Blue Lake Biotechnology, Tarsus Pharmaceuticals, Inovio Pharmaceuticals, Aegis Life, Abzyme Therapeutics, among additional organizations.

• Lyme Disease Investigational Treatments: TP-05, Amoxicillin, SHB001, VLA15, mRNA-1975, VLA15, among others.

• Lyme Disease Therapeutic Evaluation by Product Category: Monotherapy, Combination, Mono/Combination

• Lyme Disease Therapeutic Evaluation by Clinical Phases: Discovery, Preclinical, Phase I, Phase II, Phase III

Stay informed in Healthcare Research - uncover future directions for the Lyme Disease Treatment landscape through this comprehensive analysis @ Lyme Disease Emerging Drugs and Major Players

Table of Contents

* Introduction

* Executive Summary

* Lyme Disease: Overview

* Pipeline Therapeutics

* Therapeutic Assessment

* Lyme Disease - DelveInsight's Analytical Perspective

* Late Stage Products (Phase III)

* VLA 15: Valneva

* Drug profiles in the detailed report.....

* Early Stage Products (Phase I)

* CT 38: Cortene

* Drug profiles in the detailed report.....

* Preclinical and Discovery Stage Products

* Lyme disease vaccine - Introvacc

* Drug profiles in the detailed report.....

* Inactive Products

* Lyme Disease Key Companies

* Lyme Disease Key Products

* Lyme Disease- Unmet Needs

* Lyme Disease- Market Drivers and Barriers

* Lyme Disease- Future Perspectives and Conclusion

* Lyme Disease Analyst Views

* Lyme Disease Key Companies

* Appendix

About Us

DelveInsight is a premier healthcare-oriented market research and advisory organization that delivers clients superior market intelligence and analysis to facilitate informed business strategies. Supported by a team of seasoned industry specialists and comprehensive knowledge of the life sciences and healthcare industries, we provide tailored research solutions and strategic insights to clients worldwide. Partner with us to obtain superior-quality, precise, and current intelligence to maintain competitive advantage.

Contact Us

Kanishk

kkumar@delveinsight.com